MedTrace Logo

Vaccination With PD-L1 Peptide Against Multiple Myeloma

NCT03042793 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-07-07

No results posted yet for this study

Summary

Title: Vaccination with PD-L1 peptide with Montanide against multiple myeloma after high dose chemotherapy with stem cell support. A phase I first-in-human study.

Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune checkpoint molecule PD-L1 to investigate the potential of vaccination against PD-L1 as a possible anticancer target.

Conditions

Interventions

BIOLOGICAL

PD-L1 peptide vaccine

PD-L1 peptide given subcutaneously with Montanide ISA-51

Sponsors & Collaborators

  • Lene Meldgaard Knudsen

    lead OTHER

Principal Investigators

  • Nicolai Jørgensen, MD · Center for Cancer Immune Therapy, Universityhospital Herlev and Gentofte

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-05-14
Completion
2020-05-14

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03042793 on ClinicalTrials.gov